This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Stocks in Motion

Updated from 2:57 p.m. EST

Shares of Aphton (APHT) were among the worst-performing health-related stocks Tuesday, falling 45.7% after the biopharmaceutical company said that its pancreatic cancer drug, Insegia, did not meet its primary endpoint of improving overall survival rates in a phase III clinical trial.

"While Insegia did not meet the primary endpoint, we are encouraged by results we have observed in patients who achieved an antibody response, in this case approximately 70% of patients," the company said. The company believes the positive results seen by the 70% of patients who received a combination of Insegia and chemotherapy is important because it will help the company design future clinical trials that combine Insegia and chemotherapy. Shares traded down $1.43 to $1.70.

Salix Pharmaceuticals (SLXP) fell 6.1% after the company posted in-line fourth-quarter results and forecast 2005 earnings that would match expectations. The drug developer posted fourth-quarter earnings of $3.6 million, or 9 cents a share, on sales of $28.9 million. Analysts polled by Thomson First Call were expecting earnings of 9 cents a share on sales of $28.4 million. Looking ahead, the company forecast 2005 earnings of at least 60 cents a share on sales of $150 million to $155 million. Analysts are expecting earnings of 60 cents a share on sales of $146.8 million. Shares traded down $1.09 to $16.76.

Shares of Altair Nanotechnologies (ALTI) fell 15% after the company announced the sale of 5 million shares of stock at $4.05 apiece. After the deal closes, Altair expects net proceeds of about $19.2 million. The sale price represents an 18% discount to Monday's closing price of $4.95. Altair said it would use proceeds from the offering to fund working capital and general corporate needs. Shares of Altair have climbed more than 55% since the beginning of the year. Shares traded down 74 cents to $4.21.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ALTI $0.20 0.00%
ASTM $3.10 -0.18%
CRL $62.16 -0.92%
SLXP $172.81 0.09%
TEVA $59.24 1.18%


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs